Zobrazeno 1 - 10
of 89
pro vyhledávání: '"Ghazwa B Korayem"'
Autor:
Yazed S. Alsowaida, Ghazwa B Korayem, Abrar K Thabit, Omar A. Alshaya, Rahaf S. Alsaif, Thamer A. Almangour
Publikováno v:
Saudi Pharmaceutical Journal, Vol 32, Iss 2, Pp 101937- (2024)
Background: There has been a growing demand for clinical pharmacy services in the Kingdom of Saudi Arabia (KSA) in the past 3 decades. The Ministry of Education has established agreements with several institutions in the United States to secure clini
Externí odkaz:
https://doaj.org/article/c08ab4b9f8eb4ddc9040e3b649b8248c
Autor:
Ohoud Aljuhani, Khalid Al Sulaiman, Ghazwa B Korayem, Aisha Alharbi, Ali F. Altebainawi, Shatha A. Aldkheel, Sarah G. Alotaibi, Ramesh Vishwakarma, Hanan Alshareef, Samiah Alsohimi, Mashael AlFaifi, Abdulrahman Al Shaya, Haifa A. Alhaidal, Raghad M. Alsubaie, Hessah Alrashidi, Khalid J. Albarqi, Dalal T. Alangari, Reem M. Alanazi, Noora M. Altaher, Hasan M. Al-Dorzi
Publikováno v:
Renal Failure, Vol 45, Iss 2 (2023)
Tocilizumab (TCZ) is recommended in patients with COVID-19 who require oxygen therapy or ventilatory support. Despite the wide use of TCZ, little is known about its safety and effectiveness in patients with COVID-19 and renal impairment. Therefore, t
Externí odkaz:
https://doaj.org/article/ca2f1083e62d4c88939688b4397622d0
Autor:
Raed Kensara BSc.Pharm, SCC-CCP, BCPS, Ohoud Aljuhani PharmD, Ghazwa B Korayem PharmD, Hadeel Alkofide PhD, Sumaya N Almohareb PharmD, Yousef S Alosaimi PharmD, Ali F Altebainawi PharmD, Khalid Bin saleh PharmD, Norah Al Andas PharmD, MClinPharm, Shmeylan Al Harbi PharmD, Abdullah F Al Harthi PharmD, BCCCP, Uhood Ashkan PharmD, Rema Alghamdi PharmD, Hisham A Badreldin PharmD, Awatif Hafiz PharmD, Mashael AlFaifi PharmD, Rahaf A Alqahtani PharmD, Ramesh Vishwakarma PhD, Abeer A Alenazi PharmD, Mai Alalawi PharmD, Reem mahboob BSc.pharm, Renad A Alfouzan PharmD, Layan B Al Tuhayni PharmD, Nouf Al Qahtani BSc.pharm, MSc Med. Ed, Khalid Al Sulaiman BCCCP, BCNSP, MBA, FCCM
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 29 (2023)
Atrial fibrillation (Afib) can contribute to a significant increase in mortality and morbidity in critically ill patients. Thus, our study aims to investigate the incidence and clinical outcomes associated with the new-onset Afib in critically ill pa
Externí odkaz:
https://doaj.org/article/1ccd8ccd0378447f876bc769638f9f11
Autor:
Ahmed Hamden Al-Jedai, Hajer Yousef Almudaiheem, Dema Abdulrahman Alissa, Hadi Saeed Al-Enazy, Ghazwa B Korayem, Ahlam Alghamdi, Shabab Alghamdi
Publikováno v:
PLoS ONE, Vol 17, Iss 10, p e0273836 (2022)
BackgroundThe burden of macro- and microvascular complications in patients with Type 2 diabetes mellitus (T2DM) is substantial in Middle East countries. The current study assessed the healthcare resource utilization (HCRU) and costs related to cardio
Externí odkaz:
https://doaj.org/article/dbb5f3df20154fe6b1f72eb7c7a79f41
Autor:
Ghazwa B. Korayem, Ohoud Aljuhani, Ali F. Altebainawi, Abdulrahman I. Al Shaya, Lina I. Alnajjar, Abdulrahman Alissa, Mohammed Aldhaeefi, Raed Kensara, Hessa Al Muqati, Abdulmohsen Alhuwahmel, Omar Alhuthaili, Ramesh Vishwakarma, Namareq Aldardeer, Khalid Eljaaly, Aisha Alharbi, Shmeylan Al Harbi, Abdulmalik Al Katheri, Abdulkareem M. Al Bekairy, Ahmed Aljedai, Khalid Al Sulaiman
Publikováno v:
International Journal of Infectious Diseases, Vol 122, Iss , Pp 252-259 (2022)
ABSTRACT: Objectives: Evidence supports tocilizumab (TCZ) benefit and safety in adult patients with severe COVID-19. However, its effectiveness in critically ill older adult patients remains questionable. Thus, the study aimed to evaluate the safety
Externí odkaz:
https://doaj.org/article/145f3c9134124608801970a63d78ac89
Autor:
Khalid Al Sulaiman, Ghazwa B. Korayem, Khalid Eljaaly, Ali F. Altebainawi, Omar Al Harbi, Hisham A. Badreldin, Abdullah Al Harthi, Ghada Al Yousif, Ramesh Vishwakarma, Shorouq Albelwi, Rahaf Almutairi, Maha Almousa, Razan Alghamdi, Alaa Alhubaishi, Abdulrahman Alissa, Aisha Alharbi, Rahmah Algarni, Sarah Al Homaid, Khawla Al Qahtani, Nada Akhani, Abdulaleam Al Atassi, Ghassan Al Ghamdi, Ohoud Aljuhani
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-9 (2022)
Abstract Dexamethasone showed mortality benefits in patients with COVID-19. However, the optimal timing for dexamethasone initiation to prevent COVID-19 consequences such as respiratory failure requiring mechanical ventilation (MV) is debatable. As a
Externí odkaz:
https://doaj.org/article/93e752669c424ddb94f351d703a66c25
Autor:
Khalid Al Sulaiman, Hisham A. Badreldin, Ghazwa B. Korayem, Abeer A. Alenazi, Faisal Alsuwayyid, Abdulrahman Alrashidi, Mohammed Alhijris, Faisal Almutairi, Fahad Alharthi, Ramesh Vishwakarma, Omar Al Shaya, Abdulrahman Al Amri, Saqiba Tayyab, Abdulkareem M. Al Bekairy, Ohoud Aljuhani
Publikováno v:
Thrombosis Journal, Vol 20, Iss 1, Pp 1-9 (2022)
Abstract Background The benefit of apixaban to reduce stroke risk in morbidly obese patients with nonvalvular atrial fibrillation (AF) is still undetermined. The International Society of Thrombosis and Hemostasis recommends avoiding the use of direct
Externí odkaz:
https://doaj.org/article/17b0f96e88de4b38bb8b14763be87032
Autor:
Ohoud Aljuhani, Khalid Al Sulaiman, Adel Alshabasy, Khalid Eljaaly, Abdulrahman I. Al Shaya, Haytham Noureldeen, Mohammed Aboudeif, Bodoor Al Dosari, Amina Alkhalaf, Ghazwa B. Korayem, Muneera M. Aleissa, Hisham A. Badreldin, Shmeylan Al Harbi, Abdullah Alhammad, Ramesh Vishwakarma
Publikováno v:
BMC Infectious Diseases, Vol 21, Iss 1, Pp 1-8 (2021)
Abstract Background Tocilizumab is an IgG1 class recombinant humanized monoclonal antibody that directly inhibits the IL-6 receptor. Several randomized clinical trials have evaluated its safety and efficacy in patients with coronavirus disease 2019 (
Externí odkaz:
https://doaj.org/article/c8d00252251f49ceb5ec2537a6f9c97e
Autor:
Norah S. Alsubaie, Shahad M. Al Rammah, Reema A. Alshouimi, Mohammed Y. Alzahrani, Majed S. Al Yami, Abdulaali R. Almutairi, Osamah M. Alfayez, Ghazwa B. Korayem, Omar A. Almohammed
Publikováno v:
Thrombosis Journal, Vol 19, Iss 1, Pp 1-11 (2021)
Abstract Background Venous thromboembolism (VTE) is a common complication among patients with cancer and is one of the most common causes of increased morbidity and mortality. The use of direct oral anticoagulants (DOACs) for thromboprophylaxis and t
Externí odkaz:
https://doaj.org/article/32335a3dea5b4893a4cdd3f65a009d37
Autor:
Ghazwa B. Korayem, Omar A. Alshaya, Albandari A. Alghamdi, Shahad S. Alanazi, Renad T. Almutib, Mahdi Alsaileek, Abdulrahman Alrashidi, Nasser Aldosari, Nader Bin Sheraim, Majed S. Al Yami, Omar A. Almohammed
Publikováno v:
Frontiers in Public Health, Vol 10 (2022)
BackgroundThe use of sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) in patients with type 2 diabetes mellitus (T2DM) remains limited, especially in those with other compelling indications.
Externí odkaz:
https://doaj.org/article/613787a7a0fa4b12b3f71493788079e7